Research programme: metalloenzyme inhibitors - Basilea Pharmaceutica International/Forge Therapeutics
Alternative Names: FG-DXRLatest Information Update: 28 May 2023
At a glance
- Originator Basilea Pharmaceutica International; Forge Therapeutics
- Developer Basilea Pharmaceutica International
- Class Antibacterials; Small molecules
- Mechanism of Action Metalloprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 28 May 2023 No recent reports of development identified for research development in Bacterial-infections in Switzerland
- 24 Apr 2019 Forge Therapeutics and Basilea Pharmaceutica International collaborates to discover, develop and commercialise antibiotics against metalloenzyme targets
- 24 Apr 2019 Early research in Bacterial infections in Switzerland (unspecified route)